Gossamer Bio, Inc. (FRA:4GB)

Market Cap	679.49M
Revenue (ttm)	37.54M
Net Income (ttm)	-133.10M
Shares Out	n/a
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	91
Open	2.862
Previous Close	2.930
Day's Range	2.814 - 2.862
52-Week Range	0.648 - 3.174
Beta	n/a
RSI	54.49
Earnings Date	Mar 9, 2026

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The compa...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 145
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4GB

Financial Performance

Financial numbers in USD